Asked by: Lord Keen of Elie (Conservative - Life peer)
Question to the Ministry of Justice:
To ask His Majesty's Government what preparations they have made to make chemical castration mandatory for certain serious sexual offenders, and by what date will the policy be introduced.
Answered by Lord Timpson - Minister of State (Ministry of Justice)
As part of the Government’s efforts to crackdown on sex crimes, the Government has committed to extending Medication to Manage Problematic Sexual Arousal (MMPSA) to twenty prisons, ramped up from the current four in the South West.
MMPSA is a pharmaceutical intervention prescribed by clinicians to individuals, based on clinical need; medication can be given in the form of testosterone suppressing medication known as anti-androgens and selective serotonin reuptake inhibitiors (SSRIs). There is evidence of serious medium and longer-term side effects and risks associated with taking anti-androgens, which need to be carefully monitored by clinicians whilst a patient is taking them.
MMPSA is most effective when used alongside psychological interventions which includes accredited offending behaviour programmes, coordinated support such as therapy and probation supervision. This integrated approach ensures that public safety is prioritised.
The evidence of outcomes related to a reduction in psychological distress is building. To strengthen our evidence base, the Government is going further than the Independent Sentencing Review recommendation by committing to extending and expanding the existing MMPSA feasibility pilot beyond the South-West region, to two additional regions, the North East and the North West, as the first steps towards a national roll-out. We are continuing to work closely with our partners across health and justice agencies to inform our plans for implementation throughout the Autumn.
Alongside the expansion of the pilot, we are working closely with experts to ensure all future decisions are based on strong evidence which prioritises public safety, including through our collaboration with Nottingham Trent University to conduct a Randomised Controlled Trial to understand the effectiveness of SSRIs in managing problematic sexual behaviours.
We are also conducting international research to inform our approach to MMPSA. This has included hosting an expert roundtable with international representation from Sweden and Germany, and targeted engagement with countries who use this medication, as recommended in the Review. A summary of the evidence available will be deposited in the House Library.
As the evidence builds, it is right we consider ways we can increase the use of MMPSA and we will continue to explore whether we might mandate this treatment in future.
Asked by: Lord Keen of Elie (Conservative - Life peer)
Question to the Ministry of Justice:
To ask His Majesty's Government what progress they have made in assessing the risks and benefits of chemical castration for sex offenders.
Answered by Lord Timpson - Minister of State (Ministry of Justice)
As part of the Government’s efforts to crackdown on sex crimes, the Government has committed to extending Medication to Manage Problematic Sexual Arousal (MMPSA) to twenty prisons, ramped up from the current four in the South West.
MMPSA is a pharmaceutical intervention prescribed by clinicians to individuals, based on clinical need; medication can be given in the form of testosterone suppressing medication known as anti-androgens and selective serotonin reuptake inhibitiors (SSRIs). There is evidence of serious medium and longer-term side effects and risks associated with taking anti-androgens, which need to be carefully monitored by clinicians whilst a patient is taking them.
MMPSA is most effective when used alongside psychological interventions which includes accredited offending behaviour programmes, coordinated support such as therapy and probation supervision. This integrated approach ensures that public safety is prioritised.
The evidence of outcomes related to a reduction in psychological distress is building. To strengthen our evidence base, the Government is going further than the Independent Sentencing Review recommendation by committing to extending and expanding the existing MMPSA feasibility pilot beyond the South-West region, to two additional regions, the North East and the North West, as the first steps towards a national roll-out. We are continuing to work closely with our partners across health and justice agencies to inform our plans for implementation throughout the Autumn.
Alongside the expansion of the pilot, we are working closely with experts to ensure all future decisions are based on strong evidence which prioritises public safety, including through our collaboration with Nottingham Trent University to conduct a Randomised Controlled Trial to understand the effectiveness of SSRIs in managing problematic sexual behaviours.
We are also conducting international research to inform our approach to MMPSA. This has included hosting an expert roundtable with international representation from Sweden and Germany, and targeted engagement with countries who use this medication, as recommended in the Review. A summary of the evidence available will be deposited in the House Library.
As the evidence builds, it is right we consider ways we can increase the use of MMPSA and we will continue to explore whether we might mandate this treatment in future.
Asked by: Lord Keen of Elie (Conservative - Life peer)
Question to the Ministry of Justice:
To ask His Majesty's Government what possible risk factors they have identified in the implementation of chemical castration for sex offenders, and what plans they have to mitigate against these risks when implementing the policy.
Answered by Lord Timpson - Minister of State (Ministry of Justice)
As part of the Government’s efforts to crackdown on sex crimes, the Government has committed to extending Medication to Manage Problematic Sexual Arousal (MMPSA) to twenty prisons, ramped up from the current four in the South West.
MMPSA is a pharmaceutical intervention prescribed by clinicians to individuals, based on clinical need; medication can be given in the form of testosterone suppressing medication known as anti-androgens and selective serotonin reuptake inhibitiors (SSRIs). There is evidence of serious medium and longer-term side effects and risks associated with taking anti-androgens, which need to be carefully monitored by clinicians whilst a patient is taking them.
MMPSA is most effective when used alongside psychological interventions which includes accredited offending behaviour programmes, coordinated support such as therapy and probation supervision. This integrated approach ensures that public safety is prioritised.
The evidence of outcomes related to a reduction in psychological distress is building. To strengthen our evidence base, the Government is going further than the Independent Sentencing Review recommendation by committing to extending and expanding the existing MMPSA feasibility pilot beyond the South-West region, to two additional regions, the North East and the North West, as the first steps towards a national roll-out. We are continuing to work closely with our partners across health and justice agencies to inform our plans for implementation throughout the Autumn.
Alongside the expansion of the pilot, we are working closely with experts to ensure all future decisions are based on strong evidence which prioritises public safety, including through our collaboration with Nottingham Trent University to conduct a Randomised Controlled Trial to understand the effectiveness of SSRIs in managing problematic sexual behaviours.
We are also conducting international research to inform our approach to MMPSA. This has included hosting an expert roundtable with international representation from Sweden and Germany, and targeted engagement with countries who use this medication, as recommended in the Review. A summary of the evidence available will be deposited in the House Library.
As the evidence builds, it is right we consider ways we can increase the use of MMPSA and we will continue to explore whether we might mandate this treatment in future.
Asked by: Lord Keen of Elie (Conservative - Life peer)
Question to the Ministry of Justice:
To ask His Majesty's Government what progress they have made regarding their pilot for the voluntary chemical castration of sex offenders, and whether they will provide a timeline for its implementation.
Answered by Lord Timpson - Minister of State (Ministry of Justice)
As part of the Government’s efforts to crackdown on sex crimes, the Government has committed to extending Medication to Manage Problematic Sexual Arousal (MMPSA) to twenty prisons, ramped up from the current four in the South West.
MMPSA is a pharmaceutical intervention prescribed by clinicians to individuals, based on clinical need; medication can be given in the form of testosterone suppressing medication known as anti-androgens and selective serotonin reuptake inhibitiors (SSRIs). There is evidence of serious medium and longer-term side effects and risks associated with taking anti-androgens, which need to be carefully monitored by clinicians whilst a patient is taking them.
MMPSA is most effective when used alongside psychological interventions which includes accredited offending behaviour programmes, coordinated support such as therapy and probation supervision. This integrated approach ensures that public safety is prioritised.
The evidence of outcomes related to a reduction in psychological distress is building. To strengthen our evidence base, the Government is going further than the Independent Sentencing Review recommendation by committing to extending and expanding the existing MMPSA feasibility pilot beyond the South-West region, to two additional regions, the North East and the North West, as the first steps towards a national roll-out. We are continuing to work closely with our partners across health and justice agencies to inform our plans for implementation throughout the Autumn.
Alongside the expansion of the pilot, we are working closely with experts to ensure all future decisions are based on strong evidence which prioritises public safety, including through our collaboration with Nottingham Trent University to conduct a Randomised Controlled Trial to understand the effectiveness of SSRIs in managing problematic sexual behaviours.
We are also conducting international research to inform our approach to MMPSA. This has included hosting an expert roundtable with international representation from Sweden and Germany, and targeted engagement with countries who use this medication, as recommended in the Review. A summary of the evidence available will be deposited in the House Library.
As the evidence builds, it is right we consider ways we can increase the use of MMPSA and we will continue to explore whether we might mandate this treatment in future.
Asked by: Lord Keen of Elie (Conservative - Life peer)
Question to the Ministry of Justice:
To ask His Majesty's Government what research they have conducted into countries which have a policy of chemical castration for sex offenders ahead of the proposed trial in the United Kingdom.
Answered by Lord Timpson - Minister of State (Ministry of Justice)
As part of the Government’s efforts to crackdown on sex crimes, the Government has committed to extending Medication to Manage Problematic Sexual Arousal (MMPSA) to twenty prisons, ramped up from the current four in the South West.
MMPSA is a pharmaceutical intervention prescribed by clinicians to individuals, based on clinical need; medication can be given in the form of testosterone suppressing medication known as anti-androgens and selective serotonin reuptake inhibitiors (SSRIs). There is evidence of serious medium and longer-term side effects and risks associated with taking anti-androgens, which need to be carefully monitored by clinicians whilst a patient is taking them.
MMPSA is most effective when used alongside psychological interventions which includes accredited offending behaviour programmes, coordinated support such as therapy and probation supervision. This integrated approach ensures that public safety is prioritised.
The evidence of outcomes related to a reduction in psychological distress is building. To strengthen our evidence base, the Government is going further than the Independent Sentencing Review recommendation by committing to extending and expanding the existing MMPSA feasibility pilot beyond the South-West region, to two additional regions, the North East and the North West, as the first steps towards a national roll-out. We are continuing to work closely with our partners across health and justice agencies to inform our plans for implementation throughout the Autumn.
Alongside the expansion of the pilot, we are working closely with experts to ensure all future decisions are based on strong evidence which prioritises public safety, including through our collaboration with Nottingham Trent University to conduct a Randomised Controlled Trial to understand the effectiveness of SSRIs in managing problematic sexual behaviours.
We are also conducting international research to inform our approach to MMPSA. This has included hosting an expert roundtable with international representation from Sweden and Germany, and targeted engagement with countries who use this medication, as recommended in the Review. A summary of the evidence available will be deposited in the House Library.
As the evidence builds, it is right we consider ways we can increase the use of MMPSA and we will continue to explore whether we might mandate this treatment in future.
Asked by: Lord Keen of Elie (Conservative - Life peer)
Question to the Ministry of Justice:
To ask His Majesty's Government whether they will publish (1) the names of all prisons participating in the prisoner early release scheme; and (2) the number of prisoners released from each institution.
Answered by Lord Timpson - Minister of State (Ministry of Justice)
On 07 November, the Ministry of Justice published transparency data on how many offenders were released on the first days of Tranche 1 and Tranche 2 of SDS40 (1,889 prisoners on the first day of Tranche 1, and 1,223 prisoners on the first day of Tranche 2).
SDS40 is a legal requirement that applies to all prison institutions. Data on prison releases forms a subset of prison population data which is intended for future publication. In accordance with the requirements of the Code of Practice for Official Statistics, we may not give any early indication of the contents of this statistical report.
Asked by: Lord Keen of Elie (Conservative - Life peer)
Question to the Ministry of Justice:
To ask His Majesty's Government how many prisoners have been released early under the prisoner early release scheme since its introduction, broken down by offence category.
Answered by Lord Timpson - Minister of State (Ministry of Justice)
On 07 November, the Ministry of Justice published transparency data on how many offenders were released on the first days of Tranche 1 and Tranche 2 of SDS40 (1,889 prisoners on the first day of Tranche 1, and 1,223 prisoners on the first day of Tranche 2).
SDS40 is a legal requirement that applies to all prison institutions. Data on prison releases forms a subset of prison population data which is intended for future publication. In accordance with the requirements of the Code of Practice for Official Statistics, we may not give any early indication of the contents of this statistical report.
Asked by: Lord Keen of Elie (Conservative - Life peer)
Question to the Ministry of Justice:
To ask His Majesty's Government what consultation took place with victims' groups before implementing the prisoner early release scheme; and what steps they have taken to address concerns raised by victims' groups.
Answered by Lord Timpson - Minister of State (Ministry of Justice)
Following our inheritance from the previous Government, we were forced to introduce SDS40 as an emergency measure to prevent the imminent collapse of the Criminal Justice System.
Unlike the previous Government’s disastrous early release scheme, this Government ensured that probation had time to complete pre-release work and risk assessments. We also exempted a number of offences, including sex offences, violent offences with over 4 year sentences and specific offences often linked to domestic abuse.
The implementation of SDS40 was considered at a victim support sector roundtable, and then subsequently through meetings with a sector engagement group, which includes a broad range of victims’ groups and representatives. To address the concerns raised about the amount of information available to victims about the measure and its practicalities, we published an explanation of the policy on GOV.UK and provided victim support organisations with frequently asked questions and answers to support them when engaging with victims who may be affected by the measure.
Asked by: Lord Keen of Elie (Conservative - Life peer)
Question to the Ministry of Justice:
To ask His Majesty's Government what assessment they have made of the impact of the prisoner early release scheme on reoffending rates; and what measures are in place to monitor released offenders.
Answered by Lord Timpson - Minister of State (Ministry of Justice)
Our initial operational insights suggested there was not a significant change to the use and application of recall since the implementation of SDS40. We will, however, continue to monitor this.
The number of people who have been recalled or have reoffended following release under the early release measure (SDS40) forms a subset of prison releases data which is scheduled for future publication. In accordance with the requirements of the Code of Practice for Official Statistics, we may not give any early indication of the contents of this statistical report.
Proven reoffending rates are published regularly on an annual and quarterly basis. The most recent rates are available at the following link: www.gov.uk/government/collections/proven-reoffending-statistics.
SDS40 brings forward normal release with licence conditions and offenders released under this measure are managed by probation in the standard way.
Asked by: Lord Keen of Elie (Conservative - Life peer)
Question to the Ministry of Justice:
To ask His Majesty's Government how many policy reviews and consultations the Ministry of Justice has launched since the General Election on 4 July 2024; what the subject of each review is; and what the anticipated timescales are for their completion.
Answered by Lord Ponsonby of Shulbrede
Following the election, this Government has outlined its ambitions through the Plan for Change, which sets out an ambitious set of milestones - across the missions - for this Parliament.
As the House would expect, Government continually reviews its work to ensure that it is delivering the best outcomes for the people of the United Kingdom, and that its policies continue to represent the best value for the taxpayer.
Public reviews will be available on Gov.uk as they are published.